Pharma News

Piramal Enterprises’ Consumer Products Division has entered into an agreement to acquire four brands from Pfizer Limited for a consideration of Rs 110 crore. The acquisition includes brands namely Ferradol, Neko, Sloan’s and Waterbury’s compound. Additionally the agreement also includes the trademark rights for Ferradol and Waterbury’s compound in Bangladesh and Sri Lanka. These brands hold a rich legacy and have a high consumer pull and are available in India for the past 30+ years.

Stellar Biotechnologies, Inc. and Neovacs S.A. announced their entry into a joint venture agreement to manufacture and sell conjugated therapeutic vaccines (the "Joint Venture") using Stellar's proprietary Keyhole Limpet Hemocyanin (KLH).

VolitionRx Limited announced that it is initiating a study with DKFZ, the German Cancer Research Center, to evaluate VolitionRx's NuQ blood tests for the detection of pancreatic cancer.

An international study, conducted by researchers from the Institute for Development Research (IRD), Inserm and Institut Pasteur and their Guinean partners (Donka University Hospital, Macenta Hospital, National Institute of Public Health, and University of Conakry, confirms that Ebola virus persists in the semen of survivors of the epidemic in Guinea, for up to 9 months after their recovery. These results, which recall the importance of monitoring survivors in order to prevent the risks of new epidemic outbreaks, are published in the Journal of Infectious Diseases on 3 May 2016.

Edge Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational product EG-1962 for the treatment of subarachnoid hemorrhage (SAH).

Aurobindo Pharma Limited announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Zolmitriptan Tablets, 2.5 mg and 5 mg. This product is expected to be launched in Q2 FY16-17.

Caladrius Biosciences, Inc., announces that its product candidate CLBS03 (autologous expanded polyclonal regulatory T cells, or Tregs) for the treatment of recent-onset type 1 diabetes (“T1D”) was granted orphan-drug designation by the US Food and Drug Administration (“FDA”) for the treatment of type 1 diabetes mellitus with residual beta cell function.

H3 Biomedicine Inc., announced that the U.S. Food and Drug Administration (FDA) accepted the company’s Investigational New Drug (IND) application to begin Phase 1 clinical trials for its lead oncology drug candidate H3B-8800. The compound is an oral and selective small molecule modulator of splicing factor 3b subunit 1 (SF3B1), which is being developed by H3 Biomedicine as an anticancer therapeutic agent for the potential treatment of select hematologic malignancies.

NinePoint Medical, Inc., has received US Food and Drug Administration (FDA) 510(k) clearance to market its Real-time Targeting feature for its flagship product, the NvisionVLE Imaging System. In addition, the first procedures with this new system were performed at Beth Israel Deaconess Medical Center in Boston, Massachusetts.

[adsense:336x280:8701650588]

The European Commission has granted orphan drug status to Cytori Therapeutics' broad range of Cytori Cell Therapy formulations when used for the treatment of hand dysfunction and Raynaud’s Phenomenon in patients with scleroderma.